Sydney M Crago

Zeba Syed, MD, from Wills Eye Hospital discussed their research on corneal swelling and dynamics during corneal collagen crosslinking at the 2023 ASCRS annual meeting in San Diego.

Sandor Palfi, Commercial Vice President of the Americas at Johnson & Johnson Vision discussed pipeline updates for the company including the ELITA femtosecond platform at the 2023 ASCRS annual meeting in San Diego.

Lowe is the VP, of Commercial Operations at Eyenovia, and discussed the FDA approval of MydCombi for mydriasis at the 2023 ASCRS annual meeting in San Diego.

Rob Weinstock, MD from the Eye Institute of West Florida presented on his experience working with the ALLY cataract femtosecond laser cataract system from LENSAR at the 2023 ASCRS annual meeting in San Diego.

Ophthalmology Times© met with Eva Liang at the 2023 ASCRS annual meeting in San Diego where she presented data on outcomes of the Rasch-scaled Catquest-9SF questionnaire before and after implantation of the enVista toric lens.

Jim Mazzo, executive chairman of Neurotech Pharmaceuticals, discussed the company's goal to slow down the progression of MacTel and their recent advancements at the ASCRS annual meeting in San Diego.

Lance Kugler, MD, recapped his presentation and findings on the safety of office-based cataract surgery with the Ophthalmology Times© team at the ASCRS annual meeting in San Diego.

Ophthalmology Times© caught up with Alice Epitropoulos at the 2023 ASCRS annual meeting in San Diego. Among her presentations at the event, she shared data regarding the visual and refractive outcomes of aberration-free monofocal hydrophobic toric IOLs.

Ophthalmology Times© spoke with Greg Kunst about Aurion BioTech's 12-month data from their recent Escalón trial 2023 at the ASCRS annual meeting in San Diego.

Stephen Coleman from Coleman Vision in Albuquerque, New Mexico, spoke with the Ophthalmology Times© team discussed the long-term outcomes with LASIK using the iDesign 2.0 software.

Ophthalmology Times® spoke with Mitch Shultz, MD at ASCRS 2023 in San Diego about the a new FDA clinical trial for a device called StableVisc being launched on the market by Bausch + Lomb.

George Waring IV, MD met with the onsite Ophthalmology Times© team to share data from his presentation on the first in-human results for the OmniVu IOL system.

Ophthalmology Times® spoke with Mitch Shultz, MD at ASCRS 2023 in San Diego where he shared insights from his presentation comparing patient results of the Hydrus stent and the iStent inject W with or without ABiC (or ab-interno canaloplasty).

Erin Powers, Vice President of Global Marketing and Product Strategy for BVI Medical stopped to talk with Ophthalmology Times© at the 2023 ASCRS meeting in San Diego, California to share the latest news from the company.

Ophthalmology Times© spoke with Richard Lewis, CMO of ViaLase at the 2023 ASCRS meeting in San Diego. There he gave out team the details of his presentation for the 2 year follow up of the first in-human study of Femtosecond Laser Image Guided High-Precision Trabeculotomy (FLigHT).

Gerd Auffarth, MD, PhD, and the chairman at the Heidelberg University Eye Clinic discussed the 7 year, long-term data for the iStent inject second generation with our team at the 2023 ASCRS meeting in San Diego.

Ophthalmology Times© spoke with Robert Lin, MD at the 2023 ASCRS meeting in San Diego, where he shared the value of using the Insight 100 by Arcscan in his practice and why it provides a safer outcome for patients.

Ophthalmology Times© met with Robert Lin, MD at the 2023 ASCRS meeting in San Diego, where he shared his experience using ICLs in his practice and the advancements that help make these devices the right choice for patients.

Ben Bergo, CEO of Visus Therapeutics discussed the data presented at ASCRS 2023 for the company's Phase 3 pivotal study, BRIO-I with our onsite team.